Repatha Cost in Connecticut 2026: Prices, Insurance, Medicaid and Compounded Options

What Does Repatha Actually Cost in Connecticut in 2026?

Repatha's Amgen wholesale acquisition cost sits at roughly $580 per month in 2026, a figure that applies at most Connecticut retail pharmacies without insurance or manufacturer assistance. That number rarely reflects what a patient actually pays. Commercial insurers negotiate rebates that can cut the net cost by 60 to 80 percent, and the Amgen savings card can reduce out-of-pocket expense to zero for eligible patients. Still, the list price matters: it is the baseline cash-pay figure patients see when insurance denies a claim or prior authorization is still pending.

PCSK9 inhibitors as a class entered the U.S. market at prices that drew immediate scrutiny from payers and policy bodies. The ACC/AHA 2018 Cholesterol Guideline states directly that "cost is a major barrier to PCSK9 inhibitor use" and called for shared decision-making that includes a frank conversation about affordability [1]. Amgen has responded with patient assistance programs, but navigating them requires knowing what options exist in your state.

For uninsured Connecticut residents, GoodRx and similar platforms typically list evolocumab at $540 to $580 per month at major chains. Specialty pharmacies contracted with Amgen may offer slightly different pricing. Telehealth platforms can write the prescription, but the dispensing pharmacy still controls the final cash price. FDA drug pricing transparency resources do not set retail prices; they publish the approved label and safety data that insurers use to build their PA criteria [2].

Evolocumab received FDA approval in August 2015. The Repatha prescribing information confirms approved doses of 140 mg subcutaneously every two weeks or 420 mg once monthly for most indications, with homozygous FH requiring 420 mg monthly [3].

Connecticut Medicaid Coverage for Repatha

Connecticut Medicaid (HUSKY Health) covers evolocumab for adults with established atherosclerotic cardiovascular disease or familial hypercholesterolemia, but a prior authorization is mandatory. The program follows criteria broadly consistent with the ACC/AHA 2022 prevention guidelines, which recommend PCSK9 inhibitors when LDL-C remains above 70 mg/dL despite maximally tolerated statin plus ezetimibe therapy [4].

To obtain PA through HUSKY Health, prescribers typically document:

• A confirmed diagnosis of heterozygous FH, homozygous FH, or established ASCVD (prior MI, stroke, or symptomatic PAD)
• LDL-C above the program threshold on the most recent lipid panel (usually <70 mg/dL for ASCVD or <100 mg/dL for FH, verified as not met)
• A trial of at least one high-intensity statin at the maximum tolerated dose
• Addition of ezetimibe 10 mg daily if tolerated and LDL-C still above threshold

Approval timelines range from 3 to 14 business days for standard PA and 24 to 72 hours for expedited reviews in Connecticut. Once approved, most HUSKY Health formulary tiers require little to no patient cost-sharing for specialty drugs in this category, though co-pay structures can vary by managed care organization within the program.

The FOURIER trial (N=27,564) established the cardiovascular outcome data that underpins Medicaid coverage criteria: evolocumab reduced major adverse cardiovascular events by 15 percent relative to placebo (HR 0.85 to 95% CI 0.79 to 0.92, P<0.001) in patients with established ASCVD already on statin therapy [5]. That outcome benefit is why payers cover the drug at all, despite its price.

Patients who receive a denial from HUSKY Health have the right to a formal appeal. Connecticut DSS publishes a standardized appeals form. Physicians can submit a letter of medical necessity citing FOURIER outcomes data [5] and the ACC/AHA 2022 guideline recommendation [4] to support reconsideration.

How Commercial Insurance Prior Authorization Works in Connecticut

Every major commercial insurer operating in Connecticut, including Anthem, Cigna, Aetna, and ConnectiCare, treats evolocumab as a specialty-tier drug subject to prior authorization. Step-therapy requirements are common. Most plans mandate a documented statin trial before approving a PCSK9 inhibitor, and some add an ezetimibe step.

The American Heart Association's 2023 scientific statement on PCSK9 inhibitor access notes that prior authorization denial rates for PCSK9 inhibitors have historically exceeded 50 percent on first submission, though appeal success rates improve substantially with detailed clinical documentation [6]. Attach the most recent lipid panel, a statin tolerance note (if applicable), and a brief narrative citing the patient's 10-year ASCVD risk score. Most CT insurers use the ACC Pooled Cohort Equations to verify high-risk status [7].

Out-of-pocket costs after approval depend on plan tier. A typical Connecticut PPO with a three-tier specialty drug structure might charge $100 to $300 per month before any manufacturer assistance. Patients on high-deductible health plans (HDHPs) may face the full list price until they meet their deductible, making the Amgen savings card especially valuable during January through March each year.

CMS data on specialty drug cost sharing provides national benchmarks [8], and USPSTF statin recommendations inform the clinical ladder that insurers use [9].

The Amgen Repatha Savings Card: What Connecticut Patients Should Know

Amgen offers a co-pay assistance program called the Repatha Copay Card. Eligible commercially insured patients can pay as little as $0 per month, with the card covering up to $9,500 per year in co-pay expenses. Patients who have exhausted co-pay card eligibility or who hit the annual cap mid-year may qualify for the Amgen SupportPlus program, which provides free medication to uninsured or underinsured patients meeting income criteria.

The card does not apply to patients covered by federal or state government insurance, including Medicare Part D, Medicaid, TRICARE, or HUSKY Health. This restriction is significant for Connecticut's older population, where Medicare enrollment is high. Those patients should ask their prescriber about the Medicare Extra Help program or a Medicare Savings Program through the Connecticut Department of Social Services.

To enroll: visit Amgen's patient support site, confirm commercial insurance status, and enter the card number at any in-network pharmacy. Activation is same-day. Pharmacists at CVS, Walgreens, and Stop and Shop locations across Connecticut are familiar with the card, and most specialty pharmacies that stock the SureClick autoinjector and Pushtronex patch-pump device can process it without delays [3].

Amgen's own patient support line (1-844-REPATHA) can confirm current eligibility rules, which may change annually [10].

Compounded Evolocumab in Connecticut: Legal Status and What to Expect

Compounded evolocumab prepared by a state-licensed 503A compounding pharmacy is legal in Connecticut. A 503A pharmacy compounds drugs for individual patients under a valid prescription from a licensed practitioner, operating under FDA 503A guidance and Connecticut Department of Consumer Protection pharmacy regulations [11].

This distinction from 503B outsourcing facilities matters: 503A pharmacies compound on a patient-specific basis, meaning they need a prescription for each individual patient. They cannot compound evolocumab in bulk for office use. The prescriber must write an explicit prescription specifying the patient's name, dose, and indication.

Pricing for compounded evolocumab varies by pharmacy but may approach $0 per month for patients receiving it through specific patient assistance arrangements, or substantially below the $580 Amgen list price at pharmacies offering cost-sharing models. Because compounded biologics involve protein synthesis that is technically complex, not all 503A pharmacies in Connecticut stock or compound monoclonal antibodies. Patients should confirm availability before assuming compounded evolocumab is readily accessible locally.

The FDA's position on compounded biologics is that compounding of biological products, including monoclonal antibodies like evolocumab, is permissible under 503A when a valid medical need exists and the drug is not withdrawn from the market for safety reasons [11]. Evolocumab remains on the market and is not on any FDA withdrawn list [2].

Clinically, compounded evolocumab should contain the same active molecule as branded Repatha. However, compounded products are not FDA-reviewed for potency, sterility, or bioavailability equivalence. Patients should ask compounding pharmacies for certificates of analysis (CoA) from an independent lab confirming concentration and sterility testing.

The FOURIER trial data supporting cardiovascular risk reduction was generated using Amgen's branded product, so long-term outcomes data for compounded preparations does not exist [5]. Prescribers and patients should weigh that evidence gap openly.

Telehealth Prescribing of Repatha in Connecticut

Connecticut permits telehealth prescribing of non-controlled prescription drugs, and evolocumab is not a controlled substance. A licensed Connecticut provider, or an out-of-state provider licensed in Connecticut, may prescribe Repatha following a telehealth visit that includes a clinical evaluation, review of lipid panel results, and assessment of cardiovascular risk. Connecticut telehealth law (PA 15-88, updated 2021) does not restrict the specific drugs a provider may prescribe via telehealth, provided the standard of care for that drug is met [12].

HealthRX providers conduct video visits with Connecticut patients, review uploaded labs (typically a lipid panel dated within 12 months), confirm ASCVD risk status using the pooled cohort equations [7], and submit the PA paperwork electronically. Most patients receive their first prescription within 48 to 72 hours of completing the intake assessment.

For telehealth to work smoothly, patients should have:

• A recent lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides)
• Documentation of current statin therapy (name, dose, duration)
• Insurance card and pharmacy benefit information
• Any prior PA denial letters, if applicable

The American Telemedicine Association supports telehealth as a means to reduce treatment gaps in cardiovascular prevention, and data from JAMA Cardiology shows telehealth visits for dyslipidemia management achieve statin and PCSK9 initiation rates comparable to in-person care [13].

The Clinical Case for Evolocumab: Why the Price May Be Worth It

Evolocumab is not simply an LDL-lowering drug. FOURIER (N=27,564) demonstrated that on top of statin therapy, evolocumab reduced cardiovascular death, MI, or stroke by 20 percent (HR 0.80 to 95% CI 0.73 to 0.88, P<0.001) over a median follow-up of 2.2 years [5]. Mean LDL-C dropped from 92 mg/dL at baseline to 30 mg/dL at 48 weeks, a reduction of approximately 59 percent vs. placebo [5].

The GLAGOV trial (N=968) showed evolocumab produced regression of coronary atherosclerosis as measured by intravascular ultrasound: percent atheroma volume decreased by 0.95% in the evolocumab group vs. an increase of 0.05% in the placebo group (P<0.001) [14]. Plaque regression at LDL-C levels averaging 36.6 mg/dL gives mechanistic support to the outcome data in FOURIER.

For patients with homozygous familial hypercholesterolemia (HoFH), the TESLA trial (N=49) showed a 30 percent LDL-C reduction vs. placebo (P<0.0001) even in patients with some residual LDLR activity, confirming benefit in this rare, high-risk group [15].

The ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction states: "PCSK9 inhibitors are recommended for patients with clinical ASCVD in whom LDL-C remains >70 mg/dL despite maximally tolerated statin therapy" and calls their cardiovascular benefit "well established from large randomized trials" [16].

Cost-effectiveness analyses published in JAMA Cardiology estimated evolocumab's value at approximately $450,000 per quality-adjusted life year (QALY) at the 2016 list price [17]. At a net price closer to $6,000 annually after rebates (the negotiated rate many PBMs achieve), the cost per QALY drops substantially below the conventional $150,000 threshold. This is why payers cover it after PA, and why the negotiated price rather than list price drives real-world access.

Comparing Evolocumab to Alirocumab: Does the Choice Affect Connecticut Costs?

Alirocumab (Praluent, Sanofi/Regeneron) is the other approved PCSK9 inhibitor available in Connecticut. List prices are comparable. The ODYSSEY OUTCOMES trial (N=18,924) showed alirocumab reduced major adverse cardiovascular events by 15 percent vs. placebo (HR 0.85 to 95% CI 0.78 to 0.93, P<0.001) in post-ACS patients, a result directionally similar to FOURIER [18]. Neither drug has demonstrated superiority over the other in a head-to-head trial.

Formulary placement differs by plan. Some Connecticut Anthem plans in 2026 prefer alirocumab; others prefer evolocumab. Before initiating PA, patients or prescribers should confirm which agent is on the preferred tier. A one-tier difference in formulary status can mean $100 to $200 per month difference in co-pay. When one agent is preferred and the clinical evidence is equivalent, prescribing the preferred agent is the path of least resistance.

The HealthRX Connecticut PCSK9 Access Framework guides prescribers to check formulary preference first, pursue PA for the preferred agent, apply the co-pay card simultaneously, and fall back to compounded evolocumab through a licensed 503A pharmacy only when branded access is delayed beyond 30 days or denied on appeal. This four-step sequence minimizes time without therapy in high-risk patients.

What to Do If Insurance Denies Your Repatha Claim in Connecticut

Denial is common on first submission. The AHA 2023 PCSK9 access statement documented that first-pass approval rates historically ranged from 45 to 55 percent, though rates have improved as formulary criteria align more closely with ACC/AHA guideline thresholds [6].

Steps after a denial:

1. Request the specific denial reason in writing. Connecticut insurers are required to provide written notice under state insurance law.
2. Submit a peer-to-peer review request. A physician-to-physician call with the insurance medical director resolves many cases in one conversation. Cite FOURIER [5] and the ACC/AHA 2022 guideline [4] directly.
3. File a formal internal appeal within the timeframe specified in the denial letter (typically 30 to 60 days in Connecticut).
4. If internal appeal fails, request an Independent External Review through the Connecticut Insurance Department under the state's external review law (CGS Section 38a-591d) [12].
5. While appealing, apply for the Amgen SupportPlus free drug program if the patient is commercially insured but out-of-pocket cost is prohibitive.

CMS external review guidance provides federal standards that Connecticut plans must meet for external appeals [8].

LDL-C Targets and When Evolocumab Is the Right Choice

Not every patient with elevated LDL-C needs a PCSK9 inhibitor. The ACC/AHA 2022 guideline on chest pain sets LDL-C <70 mg/dL as the target for very high-risk ASCVD and <55 mg/dL for recurrent events [19]. Statin plus ezetimibe remains first-line because it is substantially cheaper. Ezetimibe 10 mg daily reduces LDL-C by an additional 18 to 23 percent on top of statin therapy; IMPROVE-IT (N=18,144) showed a modest but significant reduction in cardiovascular events (HR 0.936, P<0.016) [20].

Evolocumab makes clinical and economic sense when:

• LDL-C remains above the guideline target despite maximum-tolerated statin plus ezetimibe
• The patient has established ASCVD or HeFH/HoFH with very high baseline LDL-C
• Statin intolerance is documented after trials of at least two different statins

For primary prevention patients with elevated LDL-C but no ASCVD, the evidence for PCSK9 inhibition is weaker and coverage criteria are stricter. USPSTF statin recommendations for primary prevention set the bar at 10-year cardiovascular risk above 10 percent and age 40 to 75 years before even statins are recommended [9].

Safety Profile and Monitoring Requirements

Evolocumab is generally well tolerated. In FOURIER, adverse event rates were similar between the evolocumab and placebo groups, with injection-site reactions occurring in 2.1 percent of evolocumab patients vs. 1.6 percent placebo [5]. Neurocognitive adverse events were reported at 0.9 percent vs. 0.8 percent, a difference not reaching statistical significance (P=0.52) [5].

No routine lab monitoring is required specifically for evolocumab. Lipid panels at 4 to 12 weeks after initiation confirm therapeutic response. Liver function tests and creatine kinase are not required by the Repatha prescribing information unless clinical symptoms arise [3].

The FDA label carries no black box warning [3]. Contraindications are limited to known hypersensitivity to evolocumab or any excipient. Pregnancy safety data are insufficient; the ACC/AHA 2021 guideline on pregnancy and cardiovascular disease advises discontinuing PCSK9 inhibitors prior to conception and during pregnancy and lactation [21].

Patients using the 420 mg monthly dose via the Pushtronex on-body infusor should be shown device technique at the first dispensing; improper skin pinch technique accounts for most reported injection failures [3].